139 related articles for article (PubMed ID: 7920315)
21. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
Matsumura T; Narimatsu H; Kami M; Yuji K; Kusumi E; Hori A; Murashige N; Tanaka Y; Masuoka K; Wake A; Miyakoshi S; Kanda Y; Taniguchi S
Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
[TBL] [Abstract][Full Text] [Related]
27. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.
Bacigalupo A; Tedone E; Sanna MA; Moro F; Van Lint MT; Grazi G; Balestreri M; Frassoni F; Occhini D; Gualandi F
Haematologica; 1992; 77(6):507-13. PubMed ID: 1337746
[TBL] [Abstract][Full Text] [Related]
28. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin.
Bacigalupo A; Oneto R; Bruno B; Soracco M; Lamparelli T; Gualandi F; Occhini D; Raiola A; Mordini N; Berisso G; Bregante S; Dini G; Lombardi A; Lint MV; Brand R
Bone Marrow Transplant; 1999 Sep; 24(6):653-9. PubMed ID: 10490732
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study.
Maltezou H; Whimbey E; Abi-Said D; Przepiorka D; Champlin R; Goodrich J
Bone Marrow Transplant; 1999 Sep; 24(6):665-9. PubMed ID: 10490734
[TBL] [Abstract][Full Text] [Related]
30. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience.
Bacigalupo A; Zikos P; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Mordini N; Bregante S; Berisso G; Vitale V; Sessarego M; Marmont AM
Exp Hematol; 1998 May; 26(5):409-14. PubMed ID: 9590657
[TBL] [Abstract][Full Text] [Related]
32. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
Nguyen Q; Champlin R; Giralt S; Rolston K; Raad I; Jacobson K; Ippoliti C; Hecht D; Tarrand J; Luna M; Whimbey E
Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
[TBL] [Abstract][Full Text] [Related]
33. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T
Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050
[TBL] [Abstract][Full Text] [Related]
34. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
[TBL] [Abstract][Full Text] [Related]
35. Cytomegalovirus infection after bone marrow transplantation in children.
Castagnola E; Cappelli B; Erba D; Rabagliati A; Lanino E; Dini G
Hum Immunol; 2004 May; 65(5):416-22. PubMed ID: 15172440
[TBL] [Abstract][Full Text] [Related]
36. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
[TBL] [Abstract][Full Text] [Related]
37. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
[TBL] [Abstract][Full Text] [Related]
38. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation.
Stocchi R; Szydlo R; Craddock C; Kanfer E; Apperley JF; Goldman JM; Ward KN
Bone Marrow Transplant; 1999 Apr; 23(7):705-9. PubMed ID: 10218848
[TBL] [Abstract][Full Text] [Related]
39. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
[TBL] [Abstract][Full Text] [Related]
40. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
